Inozyme Pharma Inc expected to post a loss of 45 cents a share - Earnings Preview

Inozyme Pharma

05/05/2023 19:32

* Inozyme Pharma Inc  INZY.OQ   INZY.O  is expected to show
no
change in quarterly revenue when it reports  results on May 8
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Inozyme Pharma Inc
is for
a loss of 45 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $17.5​, above​ its last closing price of $5.86. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.42       -0.45      -0.42     Beat    7
 Sep. 30 2022  -0.43       -0.43      -0.38     Beat    12.5
 Jun. 30 2022  -0.48       -0.48      -0.38     Beat    20.6​
 Mar. 31 2022  -0.82       -0.82      -0.71     Beat    13.6
 ​​Dec.        -0.72       -0.68      -0.79     Missed  -15.3
 31 2021                                                
 Sep. 30 2021  -0.60       -0.61      -0.60     Beat    1.7​
 Jun. 30 2021  -0.57       -0.57      -0.53     Beat    7
 Mar. 31 2021  -0.54       -0.54      -0.47     Beat    13.2
 This summary was machine generated May 5 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated